Could infusions of cell 'Packages' repair failing hearts?

NCT ID NCT05774509

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial investigates whether intravenous infusions of tiny particles (extracellular vesicles) from heart progenitor cells can safely improve heart function in people with severe dilated cardiomyopathy and heart failure. Participants receive three infusions and are monitored for side effects and changes in heart performance. The study aims to determine if this experimental approach is safe and shows signs of benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
extracellular vesicle-enriched secretome of cardiovascular progenitor cells
What this could lead to
If successful, this approach could offer a new way to improve heart function in people with advanced heart failure who have not responded to standard treatments.
What could go wrong
This is an early Phase 1 trial with only 11 participants, so safety and effectiveness are not yet proven. There is a risk of serious side effects such as allergic reactions or heart rhythm problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital européen Georges Pompidou

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.